ADAC receives FDA clearance to market VANTAGE attenuation correction.MILPITAS, Calif.--(BUSINESS WIRE)--May 3, 1995--ADAC Laboratories (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ADAC ADAC Allgemeiner Deutscher Automobil Club (German automobile club) ADAC Aboriginal Drug and Alcohol Council ADAC Art Directors and Artists Club (Sacramento, California) ADAC Alcohol and Drug Abuse Council ) announced today that the company has received formal clearance from the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to market Vantage non-uniform attenuation Loss of signal power in a transmission. Attenuation The reduction in level of a transmitted quantity as a function of a parameter, usually distance. It is applied mainly to acoustic or electromagnetic waves and is expressed as the ratio of power densities. methodology on ADAC nuclear camera systems. Vantage non-uniform attenuation correction is a proprietary methodology developed by ADAC that significantly improves the accuracy and quality of nuclear medicine cardiac procedures. Mr. Ian Farmer, vice president of marketing for ADAC, reported, "ADAC has invested heavily in the development of technology that gives nuclear medicine an advantage in a "managed" patient care environment over other diagnostic specialties. Progressive health care providers are investing extensively in techniques and equipment that offer clear advantages in accuracy, efficiency or cost effectiveness in the delivery of patient care. Vantage is an important tool in the current health care environment and it will provide ADAC with strong differential product advantages that are consistent with the current needs being voiced by our health-care clients." VANTAGE attenuation uniquely corrects for non-uniform absorption by breast, diaphragm or other soft tissue structures commonly presented in conventional cardiac single-photon emission computerized tomography (SPECT SPECT single-photon emission computed tomography. SPECT abbr. single photon emission computed tomography SPECT, n See single photon emission computer tomography. ) nuclear medicine imaging nuclear medicine imaging, n the diagnostic imaging field that evaluates organ function by injecting isotopes into a structure and documenting the amount of radiation emanating from the tissues. procedures. Use of VANTAGE makes it possible to correct for non-uniform attenuation making interpretation for cardiac SPECT studies easier and more accurate. ADAC's VANTAGE is a major advance for nuclear medicine as it is the first commercial attenuation approach that is accurate, efficient and practical to perform. The Vantage approach employs precise narrow-beam source geometries and patent-pending electronic scanning-window techniques that eliminate scatter and minimize radiation exposure to the patient. Use of Gd-153 as the transmission source makes it possible to acquire both an emission and a transmission data set simultaneously using efficient 180 degree acquisition protocols for both thallium thallium (thăl`ēəm), metallic chemical element; symbol Tl; at. no. 81; at. wt. 204.383; m.p. 303.5°C;; b.p. about 1,457°C;; sp. gr. 11.85 at 20°C;; valence +1 or +3. and technetium technetium (tĕknē`shēəm) [Gr. technetos=artificial], artificially produced radioactive chemical element; symbol Tc; at. no. 43; mass no. of most stable isotope 98; m.p. 2,200°C;; b.p. 4,877°C;; sp. gr. 11. studies. Efficient VANTAGE protocols make it possible to achieve high throughput and accuracy -- while maintaining operative simplicity for cardiac SPECT procedures. Initial development of Vantage was conducted at Bowman Gray School of Medicine in Winston-Salem, North Carolina Winston-Salem is a city in the U.S. state of North Carolina. As of the 2000 census, the city population was 185,776; in 2004 the city annexed an additional 17,483 raising the population to 203,259. and Cedars Sinai Medical Center in Los Angeles. In addition to these sites, ADAC is sponsoring an extensive multi-center clinical trial in collaboration with a number of renowned medical centers including Northwestern University Medical Center -- Chicago, Emory University -- Atlanta and the University of Pittsburg -- Pittsburg. ADAC Laboratories is recognized as the world leader in Nuclear Medicine and the leading supplier of Radiology Information Systems in North America. The company is celebrating its 24th year of health care innovation. ADAC is headquartered in Milpitas, Calif., USA. CONTACT: ADAC Laboratories R. Weatherhead, 408/321-9100 x2762 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion